Concepedia

Publication | Open Access

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center

DOIFull Paper Access

54

Citations

20

References

2022

Year

Shuguang Ju, Chen Zhou, Chongtu Yang, Chaoyang Wang, Jiacheng Liu, Yingliang Wang, Songjiang Huang, Tongqiang Li, Yang Chen, Yaowei Bai,
Frontiers in Oncology

Abstract

TACE plus apatinib plus camrelizumab significantly improved OS, ORR, and DCR over apatinib plus camrelizumab in patients with unresectable HCC. AEs were tolerable and manageable.

References

YearCitations

Page 1